secwatch.observer — SEC 8-K summary
======================================

Issuer:     Structure Therapeutics Inc. (GPCR)
CIK:        0001888886
Form:       8-K
Filed at:   2024-12-17T23:59:59+00:00
Accession:  0001104659-24-129378
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Structure Therapeutics selects lead oral amylin agonist ACCG-2671 for obesity; Phase 1 start by end-2025
--------------------------------------------------------------------------------

- ACCG-2671 is a Dual Amylin and Calcitonin Receptor Agonist (DACRA) designed for once-daily oral dosing.
- Preclinical data show cagrilintide-like efficacy with potent target engagement and favorable safety profile.
- Phase 1 clinical development expected to begin by year end 2025.
- Company believes ACCG-2671 could serve as backbone therapy for fixed-dose oral combinations with GLP-1 candidate GSBR-1290.
- Structure is developing a series of amylin-based candidates using its GPCR structure-based drug discovery platform.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1888886/000110465924129378/0001104659-24-129378-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1888886/000110465924129378/tm2431274d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-129378

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer